Adenovirus-Mediated Somatic Genome Editing of Pten by CRISPR/Cas9 in Mouse Liver in Spite of Cas9-Specific Immune Responses

Human Gene Therapy

Volumn 26, Issue 7, 2015, Pages 432-442

  Wang, Dan ^a   Mou, Haiwei ^a   Li, Shaoyong ^a   Li, Yingxiang ^b   Hough, Soren ^a   Tran, Karen ^a   Li, Jia ^a   Yin, Hao ^c   Anderson, Daniel G ^c,d,e   Sontheimer, Erik J ^a   Weng, Zhiping ^a   Gao, Guangping ^a   Xue, Wen ^a  

^a UNIVERSITY OF MASSACHUSETTS   (United States)

^b TONGJI UNIVERSITY   (China)

^c MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^d Massachusetts Institute of Technology Cambridge   (United States)

^e HARVARD MIT DIVISION OF HEALTH SCIENCES AND TECHNOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; CRE RECOMBINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; BACTERIAL PROTEIN; CAS9 ENDONUCLEASE STREPTOCOCCUS PYOGENES; ENDONUCLEASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CRISPR CAS SYSTEM; FEMALE; GENOME; HEPATOMEGALY; HUMAN; HUMAN CELL; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNOTOXICITY; LIVER; MOUSE; NONALCOHOLIC FATTY LIVER; NONHUMAN; STREPTOCOCCUS PYOGENES; ADENOVIRIDAE; ADVERSE EFFECTS; ANIMAL; CLUSTERED REGULARLY INTERSPACED SHORT PALINDROMIC REPEAT; DISEASE MODEL; GENE THERAPY; GENE VECTOR; IMMUNOLOGY; NON-ALCOHOLIC FATTY LIVER DISEASE;

ADENOVIRIDAE; BACTERIA (MICROORGANISMS); MUS; STREPTOCOCCUS PYOGENES;

ADENOVIRIDAE; ANIMALS; BACTERIAL PROTEINS; CLUSTERED REGULARLY INTERSPACED SHORT PALINDROMIC REPEATS; CRISPR-CAS SYSTEMS; DISEASE MODELS, ANIMAL; ENDONUCLEASES; GENETIC THERAPY; GENETIC VECTORS; HUMANS; MICE; NON-ALCOHOLIC FATTY LIVER DISEASE;

EID: 84937558934     PISSN: 10430342     EISSN: 15577422     Source Type: Journal    
DOI: 10.1089/hum.2015.087     Document Type: Article

References (38)

1. Doudna JA, Charpentier E. Genome editing. The new frontier of genome engineering with CRISPRCas9. Science 2014;346:1258096.
2. Cox DB, Platt RJ, Zhang F. Therapeutic genome editing: prospects and challenges. Nature medicine 2015;21:121-131.
3. Sander JD, Joung JK. CRISPR-Cas systems for editing, regulating and targeting genomes. Nat Biotechnol 2014;32:347-355.
4. Cong L, Ran FA, Cox D, et al. Multiplex genome engineering using CRISPR/Cas systems. Science 2013;339:819-823.
5. Mali P, Yang L, Esvelt KM, et al. RNA-guided human genome engineering via Cas9. Science 2013;339:823-826.
6. Mou H, Kennedy Z, Anderson DG, et al. Precision cancer mouse models through genome editing with CRISPR-Cas9. Genome Med 2015;7:53.
7. Sanchez-Rivera FJ, Jacks T. Applications of the CRISPR-Cas9 system in cancer biology. Nat Rev Cancer 2015;15:387-395.
8. Sanchez-Rivera FJ, Papagiannakopoulos T, Romero R, et al. Rapid modelling of cooperating genetic events in cancer through somatic genome editing. Nature 2014;516:428-431.
9. Xue W, Chen S, Yin H, et al. CRISPR-mediated direct mutation of cancer genes in the mouse liver. Nature 2014;514:380-385.
10. Yin H, Xue W, Chen S, et al. Genome editing with Cas9 in adult mice corrects a disease mutation and phenotype. Nat Biotechnol 2014;32: 551-553.
11. Li Y, Park A, Mou H, et al. A versatile reporter system for CRISPR-mediated chromosomal rearrangements. Genome Biol 2015;16:111.
12. Liu F, Song Y, Liu D. Hydrodynamics-based transfection in animals by systemic administration of plasmid DNA. Gene Ther 1999;6:1258-1266.
13. Ding Q, Strong A, Patel KM, et al. Permanent alteration of PCSK9 with in vivo CRISPR-Cas9 genome editing. Circ Res 2014;115:488-492.
14. Cheng R, Peng J, Yan Y, et al. Efficient gene editing in adult mouse livers via adenoviral delivery of CRISPR/Cas9. FEBS Lett 2014;588:3954-3958.
15. Schagen FH, Ossevoort M, Toes RE, Hoeben RC. Immune responses against adenoviral vectors and their transgene products: A review of strategies for evasion. Crit Rev Oncol Hematol 2004;50:51-70.
16. Zuris JA, Thompson DB, Shu Y, et al. Cationic lipid-mediated delivery of proteins enables efficient protein-based genome editing in vitro and in vivo. Nat Biotechnol 2014;33:73-80.
17. Kim S, Kim D, Cho SW, et al. Highly efficient RNAguided genome editing in human cells via delivery of purified Cas9 ribonucleoproteins. Genome Res 2014;24:1012-1019.
18. Ran FA, Cong L, Yan WX, et al. In vivo genome editing using Staphylococcus aureus Cas9. Nature 2015;520:186-191.
19. Song MS, Salmena L, Pandolfi PP. The functions and regulation of the PTEN tumour suppressor. Nat Rev Mol Cell Biol 2012;13:283-296.
20. Horie Y, Suzuki A, Kataoka E, et al. Hepatocytespecific Pten deficiency results in steatohepatitis and hepatocellular carcinomas. J Clin Invest 2004;113:1774-1783.
21. Stiles B, Wang Y, Stahl A, et al. Liver-specific deletion of negative regulator Pten results in fatty liver and insulin hypersensitivity [corrected]. Proc Natl Acad Sci USA 2004;101:2082-2087.
22. Maddalo D, Manchado E, Concepcion CP, et al. In vivo engineering of oncogenic chromosomal rearrangements with the CRISPR/Cas9 system. Nature 2014;516:423-427.
23. DuPage M, Dooley AL, Jacks T. Conditional mouse lung cancer models using adenoviral or lentiviral delivery of Cre recombinase. Nat Protoc 2009;4:1064-1072.
24. Chen J, Zajac AJ, McPherson SA, et al. Primary adenovirus-specific cytotoxic T lymphocyte response occurs after viral clearance and liver enzyme elevation. Gene Ther 2005;12:1079-1088.
25. Michou AI, Santoro L, Christ M, et al. Adenovirusmediated gene transfer: influence of transgene, mouse strain and type of immune response on persistence of transgene expression. Gene Ther 1997;4:473-482.
26. Tao N, Gao GP, Parr M, et al. Sequestration of adenoviral vector by Kupffer cells leads to a nonlinear dose response of transduction in liver. Mol Ther 2001;3:28-35.
27. Lehrman S. Virus treatment questioned after gene therapy death. Nature 1999;401:517-518.
28. Nathwani AC, Tuddenham EG, Rangarajan S, et al. Adenovirus-associated virus vector-mediated gene transfer in hemophilia B. N Engl J Med 2011; 365:2357-2365.
29. Mingozzi F, Meulenberg JJ, Hui DJ, et al. AAV-1-mediated gene transfer to skeletal muscle in humans results in dose-dependent activation of capsid-specific T cells. Blood 2009;114:2077-2086.
30. Johnson PR, Schnepp BC, Zhang J, et al. Vectormediated gene transfer engenders long-lived neutralizing activity and protection against SIV infection in monkeys. Nat Med 2009;15:901-906.
31. Yin H, Kanasty RL, Eltoukhy AA, et al. Non-viral vectors for gene-based therapy. Nat Rev Genet 2014;15:541-555.
32. Geutskens SB, van der Eb MM, Plomp AC, et al. Recombinant adenoviral vectors have adjuvant activity and stimulate T cell responses against tumor cells. Gene Ther 2000;7:1410-1416.
33. Agne M, Blank I, Emhardt AJ, et al. Modularized CRISPR/dCas9 effector toolkit for target-specific gene regulation. ACS Synth Biol 2014;3:986-989.
34. Maeder ML, Linder SJ, Cascio VM, et al. CRISPR RNA-guided activation of endogenous human genes. Nat Methods 2013;10:977-979.
35. Gilbert LA, Horlbeck MA, Adamson B, et al. Genome-scale CRISPR-mediated control of gene repression and activation. Cell 2014;159:647-661.
36. Polstein LR, Gersbach CA. A light-inducible CRISPR-Cas9 system for control of endogenous gene activation. Nat Chem Biol 2015;11:198-200.
37. Davis KM, Pattanayak V, Thompson DB, et al. Small molecule-triggered Cas9 protein with improved genome-editing specificity. Nat Chem Biol 2015;11:316-318.
38. Dow LE, Fisher J, O'Rourke KP, et al. Inducible in vivo genome editing with CRISPR-Cas9. Nat Biotechnol 2015;33:390-394.